Media Contacts: Annick Robinson Investor Contacts: Justin Holko (438) (908)

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Media Contacts: Annick Robinson Investor Contacts: Justin Holko (438) 837-2550 (908) 740-1879 annick.robinson@merck.com"

Transcription

1 News Release FOR IMMEDIATE RELEASE Media Contacts: Annick Robinson Investor Contacts: Justin Holko (438) (908) Merck's HPV Vaccine, GARDASIL 9, now available in Canada Helps Protect Against Nine HPV types Including Types that Cause About 90% of Cervical Cancer Cases Kirkland, Quebec- April 1, Merck(NYSE: MRK), known as MSD outside the United States and Canada, announced today that GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), Merck s 9-valent human papillomavirus (HPV) vaccine, is now available in Canada. GARDASIL 9 is indicated for use in girls and women 9 to 45 years of age for the prevention of cervical, vulvar, vaginal, and anal cancers caused by HPV types 16, 18, 31, 33, 45, 52 and 58, pre-cancerous or dysplastic lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, and genital warts caused by HPV types 6 and 11. GARDASIL 9 is also approved for use in boys and men 9 to 26 years of age for the prevention of anal cancer caused by HPV types 16, 18, 31, 33, 45, 52 and 58, precancerous or dysplastic lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58, and genital warts caused by HPV types 6 and 11. GARDASIL 9 is contraindicated in individuals with hypersensitivity, including after a previous dose of GARDASIL 9 or GARDASIL [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine]. With GARDASIL 9, the medical and public health community now has the potential to help prevent 90 percent of cervical cancers caused by HPV, said Chirfi Guindo, President and Managing Director Merck Canada. This is an extraordinary opportunity to even further reduce the burden of HPV-related diseases and cancers in males and females in Canada. The human papillomavirus (HPV) is the most common sexually transmitted infection in Canada and worldwide. It is estimated that 75% of sexually active Canadian men and women will have at least one anogenital HPV infection in their lifetime, explained Dr. Vivien Brown, Family Doctor and Board Member of Immunize Canada. Vaccination remains the best method to prevent HPV infection and to protect yourself from the risk of HPV-related diseases.

2 - 2 - GARDASIL 9 includes the greatest number of HPV types in any available HPV vaccine. After HPV types 16 and 18, the five additional HPV types in GARDASIL 9 are the most common cervical cancer-causing types worldwide. The nine HPV types in GARDASIL 9 (HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58) cause approximately 90 percent of cervical cancer cases and approximately percent of high-grade cervical lesions (cervical precancers, defined as CIN 2, CIN 3 and AIS) worldwide. These seven HPV types also cause percent of HPVrelated vulvar cancers, percent of HPV-related vaginal cancers, and percent of HPV-related anal cancers. HPV types 6 and 11 cause approximately 90 percent of genital warts cases. In addition, approximately percent of cases of low-grade cervical lesions (CIN 1) are caused by the nine HPV types included in the vaccine. In clinical studies, GARDASIL 9 demonstrated high efficacy against the five additional HPV types The clinical trial program for GARDASIL 9 was designed to build upon the efficacy established in clinical trials with GARDASIL [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine]. The initial clinical program that supported the licensure of GARDASIL 9 began in 2007 and included six trials that evaluated more than 12,000 individuals who received GARDASIL 9. The efficacy of GARDASIL 9 in 16- through 26-year-old girls and women was assessed in an active comparator-controlled, double-blind, randomized clinical trial (Study 1) that included a total of 14,204 women (GARDASIL 9 = 7,099; GARDASIL = 7,105) who were enrolled and vaccinated without pre-screening for the presence of HPV infection. Participants were followed up with a median duration of 40 months (range 0 to 64 months) after the last vaccination. The primary comparison between GARDASIL 9 and GARDASIL was clinical efficacy for the five additional HPV types. Effectiveness of GARDASIL 9 against persistent infection and disease related to the original four HPV types (6, 11, 16, or 18) was inferred from non-inferiority comparisons. The primary efficacy analysis was conducted in those who received all three doses of vaccine within one year of enrollment, did not have major deviations from the study protocol, were negative (PCR negative and seronegative) to the relevant HPV type(s) prior to dose 1, and who remained PCR negative to the relevant HPV type(s) through Month 7 (perprotocol efficacy, or PPE, population).

3 - 3 - The primary efficacy evaluation was based on a composite clinical endpoint of HPV 31-, 33-, 45-, 52-, and 58-related cervical, vulvar, and vaginal cancer, and high-grade cervical/vulvar/vaginal disease [CIN 2/3 (cervical intraepithelial neoplasia 2/3) or AIS (adenocarcinoma in situ), VIN 2/3 (vulvar intraepithelial neoplasia 2/3), and VaIN 2/3 (vaginal intraepithelial neoplasia 2/3)]. Additional secondary endpoints related to HPV 31, 33, 45, 52, and 58 were also evaluated. Efficacy for all endpoints was measured starting after the Month 7 visit. In the PPE population, GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) demonstrated: 96.7 percent efficacy (95% CI; 80.9, 99.8) against the combined incidence of cervical, vaginal, and vulvar cancers, CIN 2/3, AIS, VIN 2/3, and VaIN 2/3 caused by HPV types 31, 33, 45, 52, 58 (1 case in the group that received GARDASIL 9 vs. 30 cases in the group that received GARDASIL ) percent efficacy (95% CI; 92.4, 99.9) against CIN 1 caused by HPV types 31, 33, 45, 52, 58 (1 case in the group that received GARDASIL 9 vs. 69 cases in the group that received GARDASIL ) percent efficacy (95% CI; 79.5, 99.8) against CIN 2/3 or AIS caused by HPV types 31, 33, 45, 52, 58 (1 case in the group that received GARDASIL 9 vs. 27 cases in the group that received GARDASIL ) percent efficacy (95% CI; 61.5, 99.7) against vulvar or vaginal disease caused by HPV types 31, 33, 45, 52, 58 (1 case in the group that received GARDASIL 9 vs. 16 cases in the group that received GARDASIL ) percent efficacy (95% CI; 94.4, 97.2) against persistent HPV infection 6 months or longer with HPV types 31, 33, 45, 52, 58 (35 cases in the group that received GARDASIL 9 vs. 810 cases in the group that received GARDASIL ) percent efficacy (95% CI; 94.4, 97.7) against persistent HPV infection 12 months or longer with HPV types 31, 33, 45, 52, 58 (21 cases in the group that received GARDASIL 9 vs. 544 cases in the group that received GARDASIL ) percent efficacy (95% CI; 89.7, 94.8) against abnormal Pap tests (ASC-US HR- HPV positive or worse) caused by HPV types 31, 33, 45, 52, 58 (35 cases in the group that received GARDASIL 9 vs. 462 cases in the group that received GARDASIL ) percent efficacy (95% CI; 93.6, 98.6) against biopsy caused by HPV types 31, 33, 45, 52, 58 (7 cases in the group that received GARDASIL 9 vs. 222 cases in the group that received GARDASIL ) percent efficacy (95% CI; 65.7, 96.0) against definitive therapy related to HPV types 31, 33, 45, 52, 58 (4 cases in the group that received GARDASIL 9 vs. 32 cases in the group that received GARDASIL ).

4 - 4 - Effectiveness of GARDASIL 9 against persistent infection and disease related to HPV types 6, 11, 16, or 18 was inferred from non-inferiority comparisons of geometric mean titers (GMTs) in 16- through 26-year-old girls and women following vaccination with GARDASIL 9 with those following vaccination with GARDASIL [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine]. Antibody responses for HPV 6, 11, 16, and 18 (measured by GMTs and seroconversion rates at Month 7) for GARDASIL 9 among young women 16 to 26 years of age were non-inferior to those who received GARDASIL. At least 99.7 percent of individuals included in the analysis for each HPV type became seropositive by Month 7. Immunogenicity of GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) Prior vaccination strategies have shown that the ideal time to administer a vaccine is before exposure to the infection. Immunogenicity studies for GARDASIL 9 were used for the adolescent population (9- to 15-year-old girls and boys) because adolescents are not likely to have been exposed to genital HPV types. Immunogenicity studies for GARDASIL 9 in adolescents (9- to 15-year-olds) are similar to that previously established and used in the clinical program for GARDASIL as a basis for licensure in this population. Merck conducted two immunogenicity studies to support effectiveness of GARDASIL 9 in adolescents. In Study 2, effectiveness of GARDASIL 9 against persistent infection and disease related to vaccine HPV types in 9- through 15-year-old girls and boys was inferred from non-inferiority comparison of GMTs following vaccination with GARDASIL 9 among 9- to 15- year-old girls and boys with those among 16- through 26-year-old girls and women. The primary analyses were conducted in the per-protocol population, which included individuals who received all three vaccinations within one year of enrollment, did not have major deviations from the study protocol, and were HPV-naïve (seronegative to the relevant HPV type(s) prior to dose 1 and among female subjects 16 through 26 years of age, PCR negative to the relevant HPV type(s) prior to dose 1 through Month 7). In this study, anti-hpv GMTs at Month 7 for GARDASIL 9 among 9- through 15-year-old girls and boys were non-inferior to anti-hpv GMTs among 16- through 26-year-old women for all nine HPV types. In Study 3, effectiveness of GARDASIL 9 against persistent infection and disease related to HPV types 6, 11, 16, or 18 was inferred from non-inferiority comparisons of GMTs in 9- through 15-year-old girls following vaccination with GARDASIL 9 with those following vaccination with GARDASIL [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine]. In the per-protocol population, anti-hpv 6, 11, 16, and 18 GMTs at Month 7 for GARDASIL 9 among girls 9 through 15 years of age were non-inferior to those

5 - 5 - who received GARDASIL. At least 99.7 percent of individuals included in the analyses for each HPV type became seropositive by Month 7. Across all clinical trials with GARDASIL 9, at least 99.5 percent of individuals included in the analyses for each of the nine vaccine HPV types became seropositive by Month 7. Anti-HPV GMTs at Month 7 among 9- through 15-year-old girls and boys were comparable to anti-hpv responses among 16- through 26-year-old women in the combined database of immunogenicity studies for GARDASIL 9. Safety of GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) The safety of GARDASIL 9 was evaluated in six clinical studies that included more than 13,000 individuals. In clinical studies with GARDASIL 9: The most common ( 10%) local and systemic adverse reactions in females 16 through 26 years of age were injection-site pain (89.9%), injection-site swelling (40.0%), injection-site erythema (34.0%) and headache (14.6%). The most common ( 10%) local and systemic reactions in girls 9 through 15 years of age were injection-site pain (89.3%) injection-site swelling (47.8%), injection-site erythema (34.1%) and headache (11.4%). The most common ( 10%) local and systemic reactions in boys 9 through 15 years of age were injection-site pain (70.2%), injection-site swelling (26.0%), and injectionsite erythema (24.2%). Important Information about GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) GARDASIL 9 is contraindicated in individuals with hypersensitivity, including after a previous dose of GARDASIL 9 or GARDASIL [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine]. Syncope (fainting) may follow any vaccination, especially in adolescents and young adults. Syncope, sometimes associated with falling, has occurred after HPV vaccination. Therefore, vaccinees should be carefully observed for approximately 15 minutes after administration of GARDASIL 9. GARDASIL 9 does not eliminate the necessity for women to continue to undergo recommended cervical cancer screening. Recipients of GARDASIL 9 should not discontinue anal cancer screening if it has been recommended by a health care provider. GARDASIL 9 has not been demonstrated to provide protection against disease from vaccine HPV types to which a person has previously been exposed through sexual activity.

6 - 6 - GARDASIL 9 has not been demonstrated to protect against diseases due to HPV types other than 6, 11, 16, 18, 31, 33, 45, 52, and 58. GARDASIL 9 is not a treatment for external genital lesions; cervical, vulvar, vaginal, and anal cancers; CIN; VIN; VaIN; or AIN. Not all vulvar, vaginal, and anal cancers are caused by HPV, and GARDASIL 9 protects only against those vulvar, vaginal, and anal cancers caused by HPV 16, 18, 31, 33, 45, 52 and 58. Vaccination with GARDASIL 9 may not result in protection in all vaccine recipients. Dosage and administration for GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) GARDASIL 9 should be administered intramuscularly in the deltoid region of the upper arm or in the higher anterolateral area of the thigh at the following schedule: 0, 2 months, 6 months. About HPV and related cancers and diseases Human papillomavirus (HPV) causes virtually all cervical cancer cases. HPV also causes approximately 74 percent of vaginal cancer cases and approximately 25 percent of vulvar cancer cases in females, and approximately percent of anal cancers and genital warts in both females and males. Approximately 575,000 cases of these HPV-related cancers occur annually worldwide. Millions of cases of genital warts occur worldwide each year in females and males. Anal cancer and genital warts affect both men and women. There is no routine screening recommended for the general population to reduce the risk of anal cancer. Treatment of genital warts can be painful, and they commonly recur after treatment, especially in the first three months. About Merck Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside Canada and the United States. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching

7 - 7 - policies, programs and partnerships. For more information about our operations in Canada, visit Forward-Looking Statement This news release includes forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of These statements are based upon the current beliefs and expectations of Merck s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forwardlooking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck s 2014 Annual Report on Form 10-K and the company s other filings with the Securities and Exchange Commission (SEC) available at the SEC s Internet site ( Please consult GARDASIL 9 Product Monograph at GARDASIL 9 Consumer Information is also available at # # #

18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer

18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer News Release Media Contacts: Annick Robinson Investor Contacts: Joseph Romanelli (514) 837-2550 (908) 740-1986 Stephanie Lyttle NATIONAL Public Relations (514) 843-2365 Justin Holko (908) 740-1879 Merck

More information

One infected partner may be all it takes to get HPV.

One infected partner may be all it takes to get HPV. One infected partner may be all it takes to get HPV. HPV can cause cervical cancer in females and genital warts in males and females. Look inside to find out more. HPV=human papillomavirus HPV: What you

More information

Supplementary Information

Supplementary Information Name 001 [15] 002 [15] 004 [15] 006 [15] Subject Characteristics N = 140 (Monovalent HPV-11 Vaccine and Placebo) N = 109 (Monovalent HPV-16 Vaccine and Placebo) N = 480 (Monovalent HPV-16 Vaccine and Placebo)

More information

Brought to you by. [ your information / logo here ]

Brought to you by. [ your information / logo here ] Brought to you by [ your information / logo here ] 1 1 2 2 3 3 HPV can infect anyone Human papillomavirus (HPV) is a widespread virus that can infect most males and females in their lifetime. For most,

More information

Brought to you by [ your information / logo here ]

Brought to you by [ your information / logo here ] Brought to you by [ your information / logo here ] 1 1 2 2 3 3 HPV can infect anyone Human papillomavirus (HPV) is a widespread virus that can infect most males and females in their lifetime. For most,

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Gardasil, suspension for injection. Gardasil, suspension for injection in a pre-filled syringe. Human Papillomavirus Vaccine

More information

WPC-V501-I GARDASIL. [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant vaccine]

WPC-V501-I GARDASIL. [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant vaccine] WPC-V501-I-022011 1 GARDASIL NEW ZEALAND DATA SHEET [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant vaccine] DESCRIPTION GARDASIL is a recombinant, quadrivalent vaccine. The quadrivalent

More information

Information on: HPV vaccine. jostrust.org.uk

Information on: HPV vaccine. jostrust.org.uk Information on: HPV vaccine jostrust.org.uk HPV vaccine This booklet covers: What is the HPV vaccine? Where can girls get the vaccine? Will being vaccinated prevent all cases of cervical cancer? How effective

More information

OREGON HEALTH AUTHORITY IMMUNIZATION PROTOCOL FOR PHARMACISTS Human Papilloma Virus Vaccines (HPV)

OREGON HEALTH AUTHORITY IMMUNIZATION PROTOCOL FOR PHARMACISTS Human Papilloma Virus Vaccines (HPV) OREGON HEALTH AUTHORITY IMMUNIZATION PROTOCOL FOR PHARMACISTS Human Papilloma Virus Vaccines (HPV) Revisions as of 01-01-2016 Vaccination age changed to clients 7 years of age Removal of adolescent well

More information

HPV. Your Semi-Annual Update. Women s Health Symposium Audrey P. Garrett, MD, MPH September, 25, 2015

HPV. Your Semi-Annual Update. Women s Health Symposium Audrey P. Garrett, MD, MPH September, 25, 2015 HPV Your Semi-Annual Update Women s Health Symposium Audrey P. Garrett, MD, MPH September, 25, 2015 Disclosures Speaker Bureau, Merck Gardasil, Gardasil 9 Speaker Bureau, Hologic Cervista and Aptima Speaker

More information

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 12/2015 FULL PRESCRIBING INFORMATION: CONTENTS*

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 12/2015 FULL PRESCRIBING INFORMATION: CONTENTS* HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use GARDASIL 9 safely and effectively. See full prescribing information for GARDASIL 9. GARDASIL 9 (Human

More information

OREGON HEALTH AUTHORITY IMMUNIZATION PROTOCOL FOR PHARMICSTS HUMAN PAPILLOMAVIRUS (HPV) VACCINE QUADRAVALENT AND BIVALENT

OREGON HEALTH AUTHORITY IMMUNIZATION PROTOCOL FOR PHARMICSTS HUMAN PAPILLOMAVIRUS (HPV) VACCINE QUADRAVALENT AND BIVALENT OREGON HEALTH AUTHORITY IMMUNIZATION PROTOCOL FOR PHARMICSTS HUMAN PAPILLOMAVIRUS (HPV) VACCINE QUADRAVALENT AND BIVALENT Revisions on 2/23/2010 are based on recent Advisory Committee on Immunization Practices

More information

Immunization Healthcare Branch. Human Papillomavirus Vaccination Program Questions and Answers. Prepared by

Immunization Healthcare Branch. Human Papillomavirus Vaccination Program Questions and Answers. Prepared by Immunization Healthcare Branch Human Papillomavirus Vaccination Program Questions and Answers Prepared by Immunization Healthcare Branch (IHB), Defense Health Agency Last Updated: 02 Jan 14 www.vaccines.mil

More information

An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)

An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) Update on the recommended Human Papillomavirus (HPV) vaccine immunization schedule TO PROMOTE AND PROTECT THE HEALTH

More information

HPV Vaccination. Nate Herr MD, Stephanie Lauden MD, James MapelLentz MD, Logan Newman MD, Dawn Martin MD, MPH University of Minnesota Pediatrics

HPV Vaccination. Nate Herr MD, Stephanie Lauden MD, James MapelLentz MD, Logan Newman MD, Dawn Martin MD, MPH University of Minnesota Pediatrics HPV Vaccination Nate Herr MD, Stephanie Lauden MD, James MapelLentz MD, Logan Newman MD, Dawn Martin MD, MPH University of Minnesota Pediatrics Disclosures I have no relevant financial relationships with

More information

An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)

An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) Updated Recommendations on Human Papillomavirus (HPV) Vaccines: 9-valent HPV vaccine and clarification of minimum

More information

Summary of Key Points WHO Position Paper on Vaccines against Human Papillomavirus (HPV) October 2014

Summary of Key Points WHO Position Paper on Vaccines against Human Papillomavirus (HPV) October 2014 Summary of Key Points WHO Position Paper on Vaccines against Human Papillomavirus (HPV) October 2014 1 Background l Selected types of HPV cause cervical cancer, anogenital warts, and other anogenital and

More information

Protect Yourself + Protect Your Partner. genital HP. T H e

Protect Yourself + Protect Your Partner. genital HP. T H e Protect Yourself + Protect Your Partner genital HP T H e V Fa ct s Protect Yourself + Protect Your Partner The facts Genital human papillomavirus (/pap pil LO ma VY rus/) (HPV) is the most common sexually

More information

An Overview Cervical Cancer Screening and Cervical Intraepithelial Neoplasia (CIN)

An Overview Cervical Cancer Screening and Cervical Intraepithelial Neoplasia (CIN) An Overview Cervical Cancer Screening and Cervical Intraepithelial Neoplasia (CIN) Linda Kelly, DNP, ANP-BC Obstetrics and Gynecology Massachusetts General Hospital Sonja and Deborah Kelly Scholar February

More information

Frequently Asked Questions

Frequently Asked Questions PPFA HPV FAQ.qxd /11 2:15 PM Page 1 Frequently Asked Questions PPFA HPV FAQ.qxd /11 2:15 PM Page 2 PPFA HPV FAQ.qxd /11 2:15 PM Page 3 General Questions About HPV PPFA HPV FAQ.qxd /11 2:15 PM Page 4 PPFA

More information

The Women s Centre Human Papilloma Virus (HPV) Vaccine: Gardasil Information for Patients

The Women s Centre Human Papilloma Virus (HPV) Vaccine: Gardasil Information for Patients The Women s Centre Human Papilloma Virus (HPV) Vaccine: Gardasil Information for Patients What is the Human papilloma Virus (HPV) and why is it Important? Human papilloma virus (HPV) is the name of a family

More information

Additional 50 patients enrolled in KEYNOTE-001 with analyses planned using Merck s proprietary PD-L1 assay at one percent and 50 percent cut points

Additional 50 patients enrolled in KEYNOTE-001 with analyses planned using Merck s proprietary PD-L1 assay at one percent and 50 percent cut points News Release Media Contacts: Annick Robinson Dominique Quirion Merck NATIONAL Annick.robinson@merck.com dquirion@national.ca 514 428-2890 514 843-2302 Investor Contacts: Justin Holko: (+1 908-423-5088

More information

News Release. FOR IMMEDIATE RELEASE Media Contact: Annick Robinson (438) 837-2550 (908) 740-1898

News Release. FOR IMMEDIATE RELEASE Media Contact: Annick Robinson (438) 837-2550 (908) 740-1898 News Release FOR IMMEDIATE RELEASE Media Contact: Annick Robinson (438) 837-2550 Investor Contact: Amy Klug (908) 740-1898 Merck Receives Approval of ZEPATIER (elbasvir/grazoprevir) in Canada for the Treatment

More information

Protecting yourself from cervical cancer. The National HPV Vaccination Program.

Protecting yourself from cervical cancer. The National HPV Vaccination Program. Protecting yourself from cervical cancer The National HPV Vaccination Program www.australia.gov.au/cervicalcancer What is cervical cancer? Cervical cancer (cancer of the cervix*) is a disease where abnormal

More information

GLOBAL CONCERNS ABOUT HPV VACCINES FACT SHEET

GLOBAL CONCERNS ABOUT HPV VACCINES FACT SHEET GLOBAL CONCERNS ABOUT HPV VACCINES FACT SHEET When detected, HPV infection is easily managed and rarely proceeds to cancer Very few women with HPV develop cervical cancer HPV infections are only one of

More information

Human Papillomavirus (HPV) and Cervical Cancer Fact Sheet. Almost all cervical cancers more than 99 percent are caused by HPV. 2

Human Papillomavirus (HPV) and Cervical Cancer Fact Sheet. Almost all cervical cancers more than 99 percent are caused by HPV. 2 Fast Facts Human Papillomavirus (HPV) and Cervical Cancer Fact Sheet Human papillomavirus (HPV) is a common infection transmitted during sexual contact and those affected often do not show symptoms. 1

More information

4/30/2013 HPV VACCINE AND NORTH DAKOTA HPV IMMUNIZATION RATES HUMAN PAPILLOMAVIRUS (HPV) HUMAN PAPILLOMAVIRUS HPV CONTINUED

4/30/2013 HPV VACCINE AND NORTH DAKOTA HPV IMMUNIZATION RATES HUMAN PAPILLOMAVIRUS (HPV) HUMAN PAPILLOMAVIRUS HPV CONTINUED HPV VACCINE AND NORTH DAKOTA HPV IMMUNIZATION RATES HUMAN PAPILLOMAVIRUS (HPV) HUMAN PAPILLOMAVIRUS What is human papillomavirus (HPV)? HPV is the most common sexually transmitted infection. There are

More information

Cancer- Warts n All. Lewis Marshall Sexual Health Physician Fremantle Hospital

Cancer- Warts n All. Lewis Marshall Sexual Health Physician Fremantle Hospital Cancer- Warts n All Lewis Marshall Sexual Health Physician Fremantle Hospital What is Human Papillomavirus Human Papillomavirus (HPV) is a Double Stranded DNA virus Up to four out of five sexually active

More information

June 8, 2006. Nancy B. Miller, M.D. Medical Officer Vaccines Clinical Trial Branch

June 8, 2006. Nancy B. Miller, M.D. Medical Officer Vaccines Clinical Trial Branch June 8, 2006 From: Nancy B. Miller, M.D. Medical Officer Vaccines Clinical Trial Branch Division of Vaccines and Related Products Applications Office of Vaccines Research and Review Center for Biologics

More information

HPV IMMUNIZATION GUIDELINES AND TIPS FOR PROVIDERS

HPV IMMUNIZATION GUIDELINES AND TIPS FOR PROVIDERS HPV IMMUNIZATION GUIDELINES AND TIPS FOR PROVIDERS HPV Most types of HPV that infect humans are asymptomatic and transient There are certain oncogenic types that may persist and cause cancers of the cervix,

More information

HUMAN PAPILLOMAVIRUS VACCINE Frequently Asked Questions for Health Professionals

HUMAN PAPILLOMAVIRUS VACCINE Frequently Asked Questions for Health Professionals HUMAN PAPILLOMAVIRUS VACCINE Frequently Asked Questions for Health Professionals Produced by the National Immunisation Office in collaboration with the Health Protection Surveillance Centre Version 3 -

More information

Cervical Screening and HPV Vaccine Guidelines In Saudi Arabia. Prof. Mohammed Addar Chairmen Gyneoncology section KKUH, King Saud University

Cervical Screening and HPV Vaccine Guidelines In Saudi Arabia. Prof. Mohammed Addar Chairmen Gyneoncology section KKUH, King Saud University Cervical Screening and HPV Vaccine Guidelines In Saudi Arabia Prof. Mohammed Addar Chairmen Gyneoncology section KKUH, King Saud University Burden of HPV related cancers l l Cervical Cancer of the cervix

More information

Sex, Lies, and Vaccination: HPV - the big facts

Sex, Lies, and Vaccination: HPV - the big facts Sex, Lies, and Vaccination: HPV - the big facts FRANCOISE BAYLIS Canada Research Chair Bioethics and Philosophy February 2009 Halifax, Canada Human Papillomavirus (HPV) HPV is the most common sexually

More information

HPV Vaccines. What is HPV? Can a vaccine help prevent HPV?

HPV Vaccines. What is HPV? Can a vaccine help prevent HPV? What is HPV? HPV Vaccines HPV stands for human papilloma virus. HPVs are a group of more than 150 related viruses. Each HPV virus in the group is given a number, and is called an HPV type (for instance,

More information

Human Papillomavirus (HPV) Vaccination Program for Grade Eight Females 2007/08

Human Papillomavirus (HPV) Vaccination Program for Grade Eight Females 2007/08 STAFF REPORT ACTION REQUIRED Human Papillomavirus (HPV) Vaccination Program for Grade Eight Females 2007/08 Date: September 4, 2007 To: From: Wards: Board of Health Medical Officer of Health All Reference

More information

Pap tests and the human papillomavirus [HPV]

Pap tests and the human papillomavirus [HPV] Pap tests and the human papillomavirus [HPV] p 1 What is the human papillomavirus (HPV)? The human papillomavirus (HPV) is a very common sexually transmitted infection. It usually causes no symptoms and

More information

Cervical Cancer Screening in the Era of HPV Vaccines and HPV tests. Christine M. Peterson, MD University of Virginia School of Medicine

Cervical Cancer Screening in the Era of HPV Vaccines and HPV tests. Christine M. Peterson, MD University of Virginia School of Medicine Cervical Cancer Screening in the Era of HPV Vaccines and HPV tests Christine M. Peterson, MD University of Virginia School of Medicine Learning Objectives After participating in this session, attendees

More information

Preventing Cervical Cancer with Gardasil Jana Ogden RN, MSN, MBA-HCA, IHCC Nursing Faculty. Upon Completion of the Lesson the student will be able to:

Preventing Cervical Cancer with Gardasil Jana Ogden RN, MSN, MBA-HCA, IHCC Nursing Faculty. Upon Completion of the Lesson the student will be able to: Preventing Cervical Cancer with Gardasil Jana Ogden RN, MSN, MBA-HCA, IHCC Nursing Faculty Upon Completion of the Lesson the student will be able to: Review statistics related to cervical cancer and HPV

More information

Ten Good Reasons to Be Concerned about the Human Papillomavirus (HPV) Vaccination Campaign

Ten Good Reasons to Be Concerned about the Human Papillomavirus (HPV) Vaccination Campaign Ten Good Reasons to Be Concerned about the Human Papillomavirus (HPV) Vaccination Campaign This document is a translation and adaption of an information brochure prepared by the Federation du Québec pour

More information

The digene HPV Test. What you should know about cervical cancer. Take the test not the risk.

The digene HPV Test. What you should know about cervical cancer. Take the test not the risk. The digene HPV Test What you should know about cervical cancer Take the test not the risk www.thehpvtest.com Cervical cancer a preventable disease Part of the annual preventive medical examination by your

More information

Questions and Answers about Human Papillomavirus (HPV) Vaccine

Questions and Answers about Human Papillomavirus (HPV) Vaccine Page 1 of 5 Questions and Answers about Human Papillomavirus (HPV) Vaccine A. Information for Providers What is HPV? Human Papillomavirus, (HPV) is one of the most common sexually transmitted infections

More information

PRODUCT MONOGRAPH GARDASIL. [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine] Suspension for injection

PRODUCT MONOGRAPH GARDASIL. [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine] Suspension for injection PRODUCT MONOGRAPH GARDASIL [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine] Suspension for injection Active Immunizing Agent Merck Canada Inc. 16750 route Transcanadienne Kirkland,

More information

Vaccines against human papillomavirus in low and middle income countries: a review of safety, immunogenicity and efficacy

Vaccines against human papillomavirus in low and middle income countries: a review of safety, immunogenicity and efficacy Nakalembe et al. Infectious Agents and Cancer (2015) 10:17 DOI 10.1186/s13027-015-0012-2 REVIEW Vaccines against human papillomavirus in low and middle income countries: a review of safety, immunogenicity

More information

HPV Vaccines. What is HPV? Can a vaccine help prevent HPV?

HPV Vaccines. What is HPV? Can a vaccine help prevent HPV? What is HPV? HPV Vaccines HPV is short for human papilloma virus. HPVs are a group of more than 150 related viruses. Each HPV virus in the group is given a number, which is called an HPV type. HPVs are

More information

Making Sense of Your Pap and HPV Test Results

Making Sense of Your Pap and HPV Test Results Making Sense of Your Pap and HPV Test Results Keep this booklet until you get your test results back from your doctor. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention

More information

Vaccinating Every Adolescent Patient. Adjunct Professor of Family Medicine University of Minnesota at Mankato

Vaccinating Every Adolescent Patient. Adjunct Professor of Family Medicine University of Minnesota at Mankato Vaccinating Every Adolescent Patient Vince LaPorte LaPorte, MD Adjunct Professor of Family Medicine University of Minnesota at Mankato Funded by the Centers for Disease Control and Prevention via the Prevention

More information

Cancer of the Cervix

Cancer of the Cervix Cancer of the Cervix WOMENCARE A Healthy Woman is a Powerful Woman (407) 898-1500 A woman's cervix (the opening of the uterus) is lined with cells. Cancer of the cervix occurs when those cells change,

More information

Year 7 & 8 Human Papillomavirus (HPV) vaccination

Year 7 & 8 Human Papillomavirus (HPV) vaccination Department of Health Year 7 & 8 Human Papillomavirus (HPV) vaccination PARENT/LEGAL GUARDIAN: to have your child vaccinated, please Read this information and discuss it with your child Complete sections

More information

Human Papillomavirus Human Papillomavirus Human Papillomavirus Pathogenesis 139

Human Papillomavirus Human Papillomavirus Human Papillomavirus Pathogenesis 139 Human Papillomavirus Human papillomavirus (HPV) is the most common sexually transmitted infection in the United States. The relationship of cervical cancer and sexual behavior was suspected for more than

More information

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 04/2015

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 04/2015 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use GARDASIL safely and effectively. See full prescribing information for GARDASIL. GARDASIL [Human Papillomavirus

More information

HPV vaccination and implications for cervical cancer screening

HPV vaccination and implications for cervical cancer screening HPV vaccination and implications for cervical cancer screening F. Xavier Bosch, MD, PhD Institut Catalá d Oncología Catalan Institute of Oncology WHO/ICO Information Centre on HPV and Cervical Cancer www.who.int/hpvcentre

More information

HPV & CERVICAL CANCER POLICY & LEGISLATIVE TOOLKIT, 3 RD EDITION

HPV & CERVICAL CANCER POLICY & LEGISLATIVE TOOLKIT, 3 RD EDITION What is HPV? 1 Frequently Asked Questions HPVs, or human papillomaviruses, are common viruses that cause warts and cancers and the most common viral sexually transmitted infection (STI). There are over

More information

Vaccination to prevent cervical cancer offered to all girls in grade 7 (age 12-13)

Vaccination to prevent cervical cancer offered to all girls in grade 7 (age 12-13) About HPV-vaccination in The Norwegian Childhood Immunisation Programme Information for children and parents in English Vaccination to prevent cervical cancer offered to all girls in grade 7 (age 12-13)

More information

Human papillomavirus infection. Epidemiology Natural History Transmission. BASSH HPV Special Interest Group

Human papillomavirus infection. Epidemiology Natural History Transmission. BASSH HPV Special Interest Group Human papillomavirus infection Epidemiology Natural History Transmission Human papillomavirus infection Epidemiology Human papillomaviruses Over 100 HPV types described 1 40 can infect the genital tract

More information

Prophylaxis Against Human Papillomavirus Infections with Gardasil Vaccine by Jaime Anderson, Pharm.D.

Prophylaxis Against Human Papillomavirus Infections with Gardasil Vaccine by Jaime Anderson, Pharm.D. Mandy C. Leonard, Pharm.D., BCPS Assistant Director, Drug Information Service Editor Meghan K. Lehmann, Pharm.D., BCPS Drug Information Specialist Editor Dana L. Travis, R.Ph. Drug Information Pharmacist

More information

What is HPV and why is it so important?

What is HPV and why is it so important? Understanding HPV For many years, Pap smears have been the most effective way to tell if a woman is at risk of developing cervical cancer. The Pap smear may also identify a common viral infection called

More information

Human papillomavirus Vaccine introduced 2010 (girls only) NOTIFIABLE

Human papillomavirus Vaccine introduced 2010 (girls only) NOTIFIABLE Chapter 10 10 Vaccine introduced 2010 (girls only) NOTIFIABLE In some circumstances, advice in these guidelines may differ from that in the Summary of Product Characteristics of the vaccines. When this

More information

Third-Quarter 2015 Earnings Conference Call Executive Commentary Highlights. October 27, 2015

Third-Quarter 2015 Earnings Conference Call Executive Commentary Highlights. October 27, 2015 Third-Quarter 2015 Earnings Conference Call Executive Commentary Highlights October 27, 2015 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA This presentation of Merck & Co., Inc.,

More information

THE MAIN ADVANTAGES OF THE HPV TEST DO HPV TESTS ATTRACT A MEDICARE

THE MAIN ADVANTAGES OF THE HPV TEST DO HPV TESTS ATTRACT A MEDICARE Understanding HPV For many years, Pap smears have been the most effective way to tell if a woman is at risk of developing cervical cancer. The Pap smear may also identify a common viral infection called

More information

HPV disease. Andrea Milbourne, MD Department of Gynecologic Oncology and Reproductive Medicine UT MD Anderson Cancer Center

HPV disease. Andrea Milbourne, MD Department of Gynecologic Oncology and Reproductive Medicine UT MD Anderson Cancer Center HPV disease Andrea Milbourne, MD Department of Gynecologic Oncology and Reproductive Medicine UT MD Anderson Cancer Center Objectives Understand the burden of HPV caused disease in the US and Texas Review

More information

P r o t e c t Y o u r s e l f + P r o t e c T Y o u r P a r t n e r. genital HPV. T h e F a c t s

P r o t e c t Y o u r s e l f + P r o t e c T Y o u r P a r t n e r. genital HPV. T h e F a c t s P r o t e c t Y o u r s e l f + P r o t e c T Y o u r P a r t n e r genital HPV T h e F a c t s P r o t e c t Y o u r s e l f + P r o t e c T Y o u r P a r t n e r The facts Genital human papillomavirus

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Vaccination and Enrollment Are Discontinued in Phase II Trials of Merck's Investigational HIV Vaccine Candidate

Vaccination and Enrollment Are Discontinued in Phase II Trials of Merck's Investigational HIV Vaccine Candidate News Release FOR IMMEDIATE RELEASE Merck Contact: Mary Elizabeth Blake (215) 652-5558 Merck Investor Contact: Graeme Bell (908) 423-5185 HVTN Contact: Sarah Alexander (206) 910-3801 Vaccination and Enrollment

More information

GUIDANCE FOR THE INTRODUCTION OF HPV VACCINES IN EU COUNTRIES. Stockholm, January ecdc.europa.eu

GUIDANCE FOR THE INTRODUCTION OF HPV VACCINES IN EU COUNTRIES. Stockholm, January ecdc.europa.eu GUIDANCE FOR THE INTRODUCTION OF HPV VACCINES IN EU COUNTRIES Stockholm, January 2008 ecdc.europa.eu PREFACE The purpose of this guidance is to lay down the scientific basis for the potential introduction

More information

ECDC GUIDANCE. Introduction of HPV vaccines in European Union countries an update.

ECDC GUIDANCE. Introduction of HPV vaccines in European Union countries an update. ECDC GUIDANCE Introduction of HPV vaccines in European Union countries an update www.ecdc.europa.eu ECDC GUIDANCE Introduction of HPV vaccines in European Union countries an update This report was commissioned

More information

POSITIVE TOP-LINE RESULTS FROM THE PHASE 3 STUDY OF ROMOSOZUMAB IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS

POSITIVE TOP-LINE RESULTS FROM THE PHASE 3 STUDY OF ROMOSOZUMAB IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS News Release POSITIVE TOP-LINE RESULTS FROM THE PHASE 3 STUDY OF ROMOSOZUMAB IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS FRAME Study Met All Primary Endpoints by Reducing the Incidence of New Vertebral Fracture

More information

Human Papilloma Virus (HPV), Cancer, and HPV Vaccines -- Frequently Asked Questions

Human Papilloma Virus (HPV), Cancer, and HPV Vaccines -- Frequently Asked Questions Human Papilloma Virus (HPV), Cancer, and HPV Vaccines -- Frequently Asked Questions What are viruses? Viruses are very small -- most cannot even be seen with a regular microscope -- organisms. They cannot

More information

HPV Clinical Research and Vaccines. Rachel Winer, PhD, MPH Department of Epidemiology University of Washington rlw@u.washington.

HPV Clinical Research and Vaccines. Rachel Winer, PhD, MPH Department of Epidemiology University of Washington rlw@u.washington. HPV Clinical Research and Vaccines Rachel Winer, PhD, MPH Department of Epidemiology University of Washington rlw@u.washington.edu Epidemiology of HPV The most common STD in the US and worldwide 80% sexually

More information

High Incidence of HPV in Minors Spotlights Need for State Legislators to Consider Amending Child Consent to Treatment Laws

High Incidence of HPV in Minors Spotlights Need for State Legislators to Consider Amending Child Consent to Treatment Laws High Incidence of HPV in Minors Spotlights Need for State Legislators to Consider Amending Child Consent to Treatment Laws By Cynthia S. Marietta, J.D., LL.M. (Health Law) csmarie@central.uh.edu Introduction

More information

HPV vaccination. Béatrice Swennen, MD, MPH PROVAC Ecole de Santé Publique ULB. Diagnostic et surveillance maladies infectieuses, 19 mai 2016

HPV vaccination. Béatrice Swennen, MD, MPH PROVAC Ecole de Santé Publique ULB. Diagnostic et surveillance maladies infectieuses, 19 mai 2016 HPV vaccination Béatrice Swennen, MD, MPH PROVAC Ecole de Santé Publique ULB Diagnostic et surveillance maladies infectieuses, 19 mai 2016 HPV L1 Virus Like Particle Malik H; 2014 Arch Virol Antigen Host

More information

Human Papillomavirus (HPV) Vaccines as an Option for Preventing Cervical Malignancies: (How) Effective and Safe?

Human Papillomavirus (HPV) Vaccines as an Option for Preventing Cervical Malignancies: (How) Effective and Safe? Send Orders of Reprints at reprints@benthamscience.org Current Pharmaceutical Design, 2013, 19, 000-000 1 Human Papillomavirus (HPV) Vaccines as an Option for Preventing Cervical Malignancies: (How) Effective

More information

The HPV vaccine Beating cervical cancer A Q&A sheet for girls and their parents on the HPV vaccination from September 2014

The HPV vaccine Beating cervical cancer A Q&A sheet for girls and their parents on the HPV vaccination from September 2014 The HPV vaccine Beating cervical cancer A Q&A sheet for girls and their parents on the HPV vaccination from September 2014 Questions and answers This Q&A on HPV vaccine supports the leaflet that your daughter

More information

Final DNP Capstone Report: Improving Adolescent HPV Vaccination Rates

Final DNP Capstone Report: Improving Adolescent HPV Vaccination Rates University of Kentucky UKnowledge DNP Practice Inquiry Projects College of Nursing 2014 Final DNP Capstone Report: Improving Adolescent HPV Vaccination Rates Jessica L. Murray University of Kentucky, jessmurray6@gmail.com

More information

Dr. Valerie Jaeger Acting President Providing Leadership in Public Health Management

Dr. Valerie Jaeger Acting President Providing Leadership in Public Health Management 2 Carlton Street, Suite 1306 Toronto, Ontario M5B 1J3 Tel: (416) 595-0006 Fax: (416) 595-0030 E-mail: info@alphaweb.org alpha s members are the public health units in Ontario. alpha Sections: Boards of

More information

GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] 9883613

GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] 9883613 9883613 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. [Human Papillomavirus Quadrivalent

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Cervarix suspension for injection Human Papillomavirus vaccine [Types 16, 18] (Recombinant, adjuvanted, adsorbed) 2. QUALITATIVE

More information

Appendix 2: Education and Counseling

Appendix 2: Education and Counseling Appendix 2: Education and Counseling A. MCCSP Resources The MCCSP has a wide range of resources for the public, some of which are multilingual. HCPs are encouraged to refer their clients to the MCCSP website,

More information

HPV, Cervical Dysplasia and Cancer

HPV, Cervical Dysplasia and Cancer FACTSHEET HPV, Cervical Dysplasia and Cancer Summary Cervical dysplasia is an abnormal change in the cells of the cervix in the uterus. Early changes, called low-grade lesions by doctors, may persist and

More information

U.S. Scientific Update Aricept 23 mg Tablets. Dr. Lynn Kramer President NeuroScience Product Creation Unit Eisai Inc.

U.S. Scientific Update Aricept 23 mg Tablets. Dr. Lynn Kramer President NeuroScience Product Creation Unit Eisai Inc. U.S. Scientific Update Aricept 23 mg Tablets Dr. Lynn Kramer President NeuroScience Product Creation Unit Eisai Inc. Unmet Need in Moderate to Severe Alzheimer s Disease (AD) Ongoing clinical deterioration

More information

Men s Preventive Services: Proposed Guidelines

Men s Preventive Services: Proposed Guidelines www.menshealthlibrary.org Men s Health Network Veterans Health Council September 2011 updated January 2012 The additional preventive services for women, initiated by the passage of the Affordable Care

More information

What is CIN (cervical intra-epithelial) and what causes it?

What is CIN (cervical intra-epithelial) and what causes it? What is CIN (cervical intra-epithelial) and what causes it? This information is an extract from the booklet Understanding CIN (cervical intra-epithelial neoplasia). You may find the full booklet helpful.

More information

Leaflet 6: HPV, anal warts & anal dysplasia

Leaflet 6: HPV, anal warts & anal dysplasia Leaflet 6: HPV, anal warts & anal dysplasia Incorporating hospital and community health services, teaching and research 1 The Homerton Anal Neoplasia Service is a referral centre that provides a screening

More information

Human Papillomavirus (HPV) Vaccine Background Paper

Human Papillomavirus (HPV) Vaccine Background Paper Human Papillomavirus (HPV) Vaccine Background Paper September 2008 The designations employed and the presentation of the material in this report do not imply the expression of any opinion whatsoever on

More information

Understanding. Cervical Changes A Health Guide for Women. National Cancer Institute U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

Understanding. Cervical Changes A Health Guide for Women. National Cancer Institute U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Cancer Institute Understanding Cervical Changes A Health Guide for Women U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health This guide helped me talk with my doctor after

More information

Implications of One Dose of HPV Vaccine. Kate Cuschieri Scottish HPV Reference Laboratory SHINe Meeting 26 th April 2016

Implications of One Dose of HPV Vaccine. Kate Cuschieri Scottish HPV Reference Laboratory SHINe Meeting 26 th April 2016 Implications of One Dose of HPV Vaccine Kate Cuschieri Scottish HPV Reference Laboratory SHINe Meeting 26 th April 2016 Scottish HPV immunisation programme and associated surveillance HPV immunisation

More information

HPV, Warts and All...

HPV, Warts and All... ... Philip Dawe, BEng and John Embil, MD, FRCPC Human papillomavirus (HPV) infection has been implicated in a number of disease processes in humans, ranging from common skin warts to cervical dysplasia.

More information

Pap smears, cytology and CCHC lab work and follow up

Pap smears, cytology and CCHC lab work and follow up Pap smears, cytology and CCHC lab work and follow up What is a Pap Smear? A Pap smear (also known as the Pap test) is a medical procedure in which a sample of cells from a woman's cervix (the end of the

More information

HPV in Richard Gilson

HPV in Richard Gilson HPV in 2016 Richard Gilson Reader in Sexual Health and HIV Centre Sexual Health and HIV Research UCL Research Department of Infection and Population Health RCP-BASHH September 2016 HPV in 2016 Prevention

More information

HPV vaccines. Ian H. Frazer CHAPTER 8. 1. Introduction. KEYWORDS Cervical cancer; Vaccination; Human papillomavirus

HPV vaccines. Ian H. Frazer CHAPTER 8. 1. Introduction. KEYWORDS Cervical cancer; Vaccination; Human papillomavirus International Journal of Gynecology and Obstetrics (2006) 94 (Supplement 1), S81 -S88 www.elsevier.com/locate/ijgo CHAPTER 8 HPV vaccines Ian H. Frazer KEYWORDS Cervical cancer; Vaccination; Human papillomavirus

More information

Immunization Information for Blinn College Students

Immunization Information for Blinn College Students 1 Immunization Information for Blinn College Students *Important Information Regarding the Bacterial Meningitis Vaccine* The State passed Senate Bill 1107 in 2011 and recently Senate Bill 62 in 2013, which

More information

HUMAN PAPILLOMAVIRUS (HPV) FACT SHEET

HUMAN PAPILLOMAVIRUS (HPV) FACT SHEET HUMAN PAPILLOMAVIRUS (HPV) FACT SHEET Background Information - Human Papillomavirus HPV is the name of a group of viruses that include more than 80 different types associated with a variety of epidermal

More information

Accent on Health Obgyn, PC HPV Frequently Asked Questions

Accent on Health Obgyn, PC HPV Frequently Asked Questions 1. What is HPV? 2. How do you get HPV? 3. How common is HPV? 4. What are the symptoms of HPV? 5. Can HPV be treated? 6. What is the HPV test and how is it different from a PAP test? 7. Can the HPV test

More information

Media Contacts: Annick Robinson Investor Contacts: Teri Loxam (438) 837-2550 (908) 740-1986

Media Contacts: Annick Robinson Investor Contacts: Teri Loxam (438) 837-2550 (908) 740-1986 News Release Media Contacts: Annick Robinson Investor Contacts: Teri Loxam (438) 837-2550 (908) 740-1986 Merck Announces Initial Results for Pembrolizumab with Novel Immunotherapy Combinations from Three

More information

Sanofi Reports Positive Phase 3 Results for Toujeo (insulin glargine [rdna origin] injection, 300 U/mL)

Sanofi Reports Positive Phase 3 Results for Toujeo (insulin glargine [rdna origin] injection, 300 U/mL) PRESS RELEASE Sanofi Reports Positive Phase 3 Results for Toujeo (insulin glargine [rdna origin] injection, 300 U/mL) Meta-analysis of three late-stage trials in people with type 2 diabetes shows decreases

More information

Colposcopy Mentorship Program FAQs

Colposcopy Mentorship Program FAQs Colposcopy Mentorship Program FAQs What is the Colposcopy Mentorship Program? The ASCCP Colposcopy Mentorship Program (CMP) is a three-tiered educational program designed to improve the beginning colposcopist

More information

CERVARIX [Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant] Suspension for Intramuscular Injection Initial U.S.

CERVARIX [Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant] Suspension for Intramuscular Injection Initial U.S. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CERVARIX safely and effectively. See full prescribing information for CERVARIX. CERVARIX [Human Papillomavirus

More information

What is HPV? Low-risk HPV types. High-risk HPV types

What is HPV? Low-risk HPV types. High-risk HPV types HPV and Cancer What is HPV? HPV is short for human papilloma (PAP-uh-LO-muh) virus. HPVs are a large group of related viruses. Each HPV virus in the group is given a number, which is called an HPV type.

More information

HUMAN PAPILLOMAVIRUS VACCINE Frequently Asked Questions for Health Professionals

HUMAN PAPILLOMAVIRUS VACCINE Frequently Asked Questions for Health Professionals HUMAN PAPILLOMAVIRUS VACCINE Frequently Asked Questions for Health Professionals Produced by the National Immunisation Office in collaboration with the Health Protection Surveillance Centre Version 10.1

More information

Cervical cancer screening with the HPV test and the Pap test in women ages 30 and older

Cervical cancer screening with the HPV test and the Pap test in women ages 30 and older Cervical cancer screening with the HPV test and the Pap test in women ages 30 and older When to get tested and how to make sense of your test results If you are 30 years or older and your Pap test is normal

More information